Reasonable expansion of surgical candidates for HCC treatment.
作者信息
Butensky Samuel D, Billingsley Kevin G, Khan Sajid A
机构信息
Department of Surgery, Division of Surgical Oncology, Yale School of Medicine, New Haven, Connecticut, USA.
出版信息
Clin Liver Dis (Hoboken). 2024 May 8;23(1):e0153. doi: 10.1097/CLD.0000000000000153. eCollection 2024 Jan-Jun.
Abstract
摘要
相似文献
1
Reasonable expansion of surgical candidates for HCC treatment.合理扩大肝癌治疗手术候选者范围。
Clin Liver Dis (Hoboken). 2024 May 8;23(1):e0153. doi: 10.1097/CLD.0000000000000153. eCollection 2024 Jan-Jun.
2
Developmental artificial neural network model to evaluate the preoperative safe limit of future liver remnant volume for HCC combined with clinically significant portal hypertension.用于评估 HCC 合并临床显著门静脉高压症患者剩余肝体积术前安全限度的发育性人工神经网络模型。
Future Oncol. 2022 Jul;18(21):2683-2694. doi: 10.2217/fon-2021-1297. Epub 2022 Jun 14.
3
Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.肝癌患者与非肝癌患者的终末期肝病模型评分增加导致等待名单死亡率差异增大。
Liver Transpl. 2012 Apr;18(4):434-43. doi: 10.1002/lt.23394.
4
Current trends and recent advances in diagnosis, therapy, and prevention of hepatocellular carcinoma.肝细胞癌诊断、治疗及预防的当前趋势与最新进展
Asian Pac J Cancer Prev. 2015;16(9):3595-604. doi: 10.7314/apjcp.2015.16.9.3595.
5
Waitlist priority for hepatocellular carcinoma beyond milan criteria: a potentially appropriate decision without a structured approach.米兰标准之外的肝细胞癌候补名单优先权：一种没有结构化方法的潜在适当决策。
Am J Transplant. 2014 Jan;14(1):79-87. doi: 10.1111/ajt.12530. Epub 2013 Dec 4.
6
Reduced priority MELD score for hepatocellular carcinoma does not adversely impact candidate survival awaiting liver transplantation.肝细胞癌患者降低优先级的终末期肝病模型（MELD）评分不会对等待肝移植的候选者生存率产生不利影响。
Am J Transplant. 2006 Aug;6(8):1957-62. doi: 10.1111/j.1600-6143.2006.01411.x. Epub 2006 Jun 9.
7
Liver transplantation and waitlist mortality for HCC and non-HCC candidates following the 2015 HCC exception policy change.2015 年 HCC 例外政策变更后，肝移植和 HCC 及非 HCC 候选者的候补名单死亡率。
Am J Transplant. 2019 Feb;19(2):564-572. doi: 10.1111/ajt.15144. Epub 2018 Nov 9.
8
Expansion of the criteria for living donor liver transplantation for hepatocellular carcinoma.肝细胞癌活体肝移植标准的扩展。
Curr Opin Organ Transplant. 2016 Apr;21(2):231-7. doi: 10.1097/MOT.0000000000000294.
9
The Impact of Medicaid Expansion on Early-Stage Hepatocellular Carcinoma Care.医疗补助扩大对早期肝细胞癌治疗的影响。
Ann Surg Oncol. 2023 Aug;30(8):4589-4599. doi: 10.1245/s10434-023-13562-9. Epub 2023 May 4.
10
Exosome encapsulated ncRNAs in the development of HCC: potential circulatory biomarkers and clinical therapeutic targets.外泌体包裹的非编码RNA在肝癌发生发展中的作用：潜在的循环生物标志物和临床治疗靶点
Am J Cancer Res. 2021 Aug 15;11(8):3794-3812. eCollection 2021.
本文引用的文献
1
Sequential Y liver radioembolization and portal vein embolization: an additional strategy to downstage liver tumors and to enhance liver hypertrophy before major hepatectomies.序贯 Y 型肝脏放射性栓塞和门静脉栓塞：在大肝切除术前降期肝脏肿瘤和增强肝脏肥大的附加策略。
Langenbecks Arch Surg. 2023 Aug 28;408(1):339. doi: 10.1007/s00423-023-03083-0.
2
Cancer statistics, 2023.癌症统计数据，2023 年。
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
3
Neoadjuvant Cabozantinib and Nivolumab Converts Locally Advanced HCC into Resectable Disease with Enhanced Antitumor Immunity.新辅助卡博替尼和纳武单抗将局部晚期肝癌转化为可切除疾病并增强抗肿瘤免疫力。
Nat Cancer. 2021 Sep;2(9):891-903. doi: 10.1038/s43018-021-00234-4. Epub 2021 Jul 29.
4
Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis.伴有血管侵犯的肝细胞癌手术切除与全身治疗的比较：美国国立癌症数据库分析
Liver Cancer. 2021 Apr 23;10(5):407-418. doi: 10.1159/000515554. eCollection 2021 Sep.
5
Preoperative portal vein or portal and hepatic vein embolization: DRAGON collaborative group analysis.术前门静脉或门静脉和肝静脉栓塞：DRAGON 协作组分析。
Br J Surg. 2021 Jul 23;108(7):834-842. doi: 10.1093/bjs/znaa149.
6
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
7
Hepatocellular carcinoma.肝细胞癌。
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
8
Anatomic versus non-anatomic resection for hepatocellular carcinoma: A systematic review and meta-analysis.解剖性与非解剖性肝切除术治疗肝细胞癌：系统评价和荟萃分析。
Eur J Surg Oncol. 2018 Jul;44(7):927-938. doi: 10.1016/j.ejso.2018.04.018. Epub 2018 Apr 30.
9
Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies.肝切除术与化疗栓塞术治疗中晚期肝细胞癌的比较：高质量研究的荟萃分析。
Hepatology. 2018 Sep;68(3):977-993. doi: 10.1002/hep.29883. Epub 2018 May 21.
10
Radioembolisation and portal vein embolization before resection of large hepatocellular carcinoma.大肝细胞癌切除术前的放射性栓塞和门静脉栓塞
World J Gastroenterol. 2015 Aug 28;21(32):9666-70. doi: 10.3748/wjg.v21.i32.9666.
Zotero 插件